platoseedplatoseed
Discovering the true signals of disease to power life-changing drugs.
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
Sequence Bio is a company focused on discovering true disease signals to power faster development of medicines. They emphasize an integrated systems biology approach using founder population multi-omics, real-world patient data, and well-characterized phenotypes to create targeted discovery cohorts for both common and rare diseases.
Their platform combines systems biology with data-driven computation to identify true disease signals and shorten R&D timelines. It enables powered discovery cohorts by leveraging founder population data from Newfoundland and Labrador, with complete health records and phenotypic stratification to link variants to disease outcomes. They partner with leading pharma and biotech to shorten development timelines through custom discovery cohorts.
Who it’s for: Pharma and biotech companies seeking faster target discovery and development through population-based multi-omics and real-world data; organizations requiring custom disease discovery cohorts.
hiring/awards and notable research partnerships; named as a top employer and launching multi-disease genetic research studies
Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003). Previously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic) Best dog dad ever; 7 out of 10 human dad.
Using the immune system to cure disease
XGenomes is building the sequencing technology of the future.
